|Bid||43.53 x 0|
|Ask||43.54 x 0|
|Day's Range||42.51 - 44.18|
|52 Week Range||28.80 - 95.90|
|Beta (5Y Monthly)||0.68|
|PE Ratio (TTM)||147.46|
|Earnings Date||Mar 26, 2021|
|Forward Dividend & Yield||0.02 (0.05%)|
|Ex-Dividend Date||Sep 30, 2020|
|1y Target Est||65.34|
China's Walvax Biotechnology Co has started work on a plant to manufacture an early-stage coronavirus vaccine candidate similar to AstraZeneca PLC's product, state-backed media said on Sunday. Mass production for the proposed vaccine could begin in mid-2021, with an estimated capacity of 200 million doses a year, said Health Times, a paper run by the People's Daily. The treatment is based on a chimpanzee adenovirus to deliver materials that can trigger an immune response against the virus that causes COVID-19, a technique adopted in the candidate from AstraZeneca and Oxford University.
Sirnaomics Inc., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it has sealed its USD$105 million Series D financing. This round of funding was co-led by existing investor Rotating Boulder Fund, new investor Walvax Biotechnology Co., Ltd. and Sunshine Riverhead Capital, with support from existing investors Sangel Capital and new investors: Longmen Capital, HongTao Capital and Alpha Win Capital. Chinese Renaissance and Huatai Financial Holdings (Hong Kong) Ltd. served as the financial advisors for this round of fund raising.
Mexico is working to produce its own COVID-19 vaccines and could have one ready by next spring, according to a researcher coordinating local efforts amid a global race to tame a disease that has infected over 26.75 million people worldwide. Esther Orozco, coordinator of the scientific group that represents Mexico at the Coalition for Epidemic Preparedness Innovations, said research based on a virus that transmits the avian Newcastle disease is the most viable candidate to produce the first vaccine in Mexico. Orozco said the vaccine, developed by the private firm Laboratorio Avimex with researchers from Mexico's main public university, UNAM, and the Mexican Social Security Institute, is ready to start the first phase of testing with humans.